Acadia Pharmaceuticals Files 8-K on Financials
Ticker: ACAD · Form: 8-K · Filed: 2024-05-08T00:00:00.000Z
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: ACAD
TL;DR
ACADIA filed an 8-K detailing financial results and exhibits. Check for updates.
AI Summary
Acadia Pharmaceuticals Inc. filed an 8-K on May 08, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to its business operations. The company is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This filing provides investors with crucial updates on Acadia Pharmaceuticals' financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- ACADIA PHARMACEUTICALS INC (company) — Registrant
- May 08, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- San Diego, California (location) — Principal Executive Offices
- 000-50768 (identifier) — SEC File Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Acadia Pharmaceuticals Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 08, 2024.
Where is Acadia Pharmaceuticals Inc. headquartered?
Acadia Pharmaceuticals Inc.'s principal executive offices are located at 12830 El Camino Real, Suite 400, San Diego, California, 92130.
What is the SEC file number for Acadia Pharmaceuticals Inc.?
The SEC file number for Acadia Pharmaceuticals Inc. is 000-50768.
What is the Standard Industrial Classification code for Acadia Pharmaceuticals Inc.?
The Standard Industrial Classification code for Acadia Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 529 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-05-08 16:10:16
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ACAD The Nasdaq Stock Mar
Filing Documents
- acad-20240508.htm (8-K) — 39KB
- acad-ex99_1.htm (EX-99.1) — 161KB
- 0000950170-24-055647.txt ( ) — 323KB
- acad-20240508.xsd (EX-101.SCH) — 24KB
- acad-20240508_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On May 8, 2024, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the three months ended March 31, 2024. A copy of this press release is furnished herewith as Exhibit 99.1. Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated May 8, 2024. 104 Cover page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Acadia Pharmaceuticals Inc. Date: May 8, 2024 By: /s/ Jennifer J. Rhodes Jennifer J. Rhodes Executive Vice President, Chief Legal Officer & Secretary